Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -43.13% is 34% above its 5-year average of -65.67%, around the middle of its 5-year range (-141.48%–1.50%).
46.39% above its 12-month average of -80.45%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.11%.
RETURN ON ASSETS (ROA)
-43.13%
RETURN ON ASSETS (ROA) AVG TTM
-80.45%
RETURN ON ASSETS (ROA) AVG 3Y
-58.18%
RETURN ON ASSETS (ROA) AVG 5Y
-65.67%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+46.39%
CURRENT VS 3Y AVG
+25.87%
CURRENT VS 5Y AVG
+34.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-72.87%
vs the sector median at left
Cognition Therapeutics, Inc.
Market Cap
$83.96M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$84.00M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$83.49M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.70M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$84.75M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
Market Cap
$86.69M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
Market Cap
$81.22M
Return on Assets (ROA)
-41.09%
TTM Avg
-24.80%
3Y Avg
-25.41%
5Y Avg
-25.41%
Market Cap
$87.86M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$88.21M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $83.96M | -43.13% | -80.45% | -58.18% | -65.67% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -70.05% | -71.47% | -58.80% | -51.13% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | -79.38% | 41.63% | -36.06% | -44.84% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -74.91% | -50.52% | -40.48% | -70.00% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 8.52% | 11.64% | -8.81% | -6.61% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -41.09% | -24.80% | -25.41% | -25.41% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -107.29% | -60.42% | -51.23% | -39.69% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 1.69% | -3.62% | -6.49% | -4.78% |
| electroCore, Inc. (ECOR)vs › | $91.33M | -86.56% | -66.44% | -84.84% | -75.69% |
ROA
-43.1%
ROE
-50.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -48.54% |
| 2024-12-31 | -112.36% |
| 2023-12-31 | -73.34% |
| 2022-12-31 | 1.50% |
| 2021-12-31 | -19.81% |
| 2020-12-31 | -141.48% |
| 2019-12-31 | -93.22% |
